Market leadership Farmak dominates the Ukrainian pharmaceutical market with a portfolio of over 450 modern medicines and extensive international reach across 60 countries, indicating a strong platform for introducing new products or line extensions through existing distribution networks.

High reinvestment Annual reinvestment of up to 90% of profits into development and substantial cumulative investment in the last decade signal a growth-focused organization open to strategic partnerships, co-development, and long-term supply agreements.

Strong manufacturing EU GMP-certified production facilities, robust labs, and a technical complex position Farmak as a reliable manufacturing partner suitable for contract manufacturing, toll manufacturing, or scale-up of complex therapies.

Recent expansion Recent launches of multiple new products in 2026 and recognition as a top employer suggest momentum and capability to quickly bring products to market, making Farmak a potential partner for accelerated regulatory filing support and market access ventures.

Financial health Revenue in the mid-range hundreds of millions with strong tax contributions and a track record of growth imply solid budgeting capacity for co-investment, цен partnerships, and value-added pharmaceutical programs in collaboration with international buyers.